Journals / Turkish Journal of Endocrinology and Metabolism / 2021 / Cilt: 25 - Sayı: 1

Pheochromocytoma: 16 Years of Experience in a Single Center

Feokromasitoma: Tek Merkezde 16 Yıllık Deneyim

Pages
54–67
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Median tumor size was 40 mm (range: 9-90 mm) and the lesion size correlated significantly (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Reviewing the 16-year experience of pheochromocytoma in a tertiary referral center.
📊
Key Findings & Data:Material and Methods: The demographics data and the results of clinical, biochemical, and radiological evaluations of 67 patients who received a diagnosis of pheochromocytoma between the years 2004 and 2020 were obtained retrospectively.
💡
Conclusion & Impact:Median tumor size was 40 mm (range: 9-90 mm) and the lesion size correlated significantly (p
🔬Design:Review & Systematic Survey
📍Scope:2004 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Reviewing the 16-year experience of pheochromocytoma in a tertiary referral center. Material and Methods: The demographics data and the results of clinical, biochemical, and radiological evaluations of 67 patients who received a diagnosis of pheochromocytoma between the years 2004 and 2020 were obtained retrospectively. Results: The mean age (±SD) of the patients at the time of diagnosis was 46 years (±16.1) with a slight female predominance. The percentage of patients diagnosed due to complaints was 50.8%, while 31.2% were diagnosed during the adrenal incidentaloma screening, and 18% were diagnosed during screening for hereditary conditions. Pre-existing hypertension was detected in 56.7% of the patients, while 11.9% of the patients were diagnosed to have hypertension at the time of diagnosis. Paroxysmal pattern was observed in 53.7% of the patients and was accompanied by the classical triad of palpitation (32.8%), headache (20.9%), and sweating (14.9%) as the leading symptoms. Median tumor size was 40 mm (range: 9-90 mm) and the lesion size correlated significantly (p

Özet

Amaç: Üçüncü basamak bir üniversite hastanesinde, 16 yıllık feokromasitoma deneyiminin gözden geçirilmesi. Gereç ve Yöntemler: Bu araştırma, 2004- 2020 yılları arasında feokromasitoma tanısı almış 67 hastanın değerlendirildiği retrospektif bir çalışma olup, hastaların demografik özellikleri ve klinik, biyokimyasal ve radyolojik değerlendirmelerine ilişkin sonuçlar araştırılmıştır. Bulgular: Araştırmada, feokromositoma tanısı konulan hastaların yaş ortalaması 46 (±16,1), kadın/erkek oranı 1,2, feokromositoma ile ilişkili yakınmalarla başvurup, bu tanının konulduğu hasta oranı ise %50,8’dir. Hastalara konulan tanıların %31,2’si rastlantısal adrenal kitle araştırılması sırasında, %18’i ise genetik geçişli sendromlar araştırılırken gerçekleştirilmiştir. Hastaların %56,7’sinde tanıdan önce de hipertansiyonun bilindiği, %11.9’unda ise hipertansiyonun tanı sırasında belirlendiği görülmüştür. Hastaların %53.7’sinde tansiyon yüksekliğinin ataklar halinde ortaya çıktığı saptanmıştır. Hastalarda ataklara en sık eşlik eden belirtilerin çarpıntı (%32,8), baş ağrısı (%20,9) ve terleme (%14,9) olduğu dikkati çekmektedir. Araştırmada, ortanca tümör boyutu 40 mm (9-90) saptanmış ve tümör boyutu ile idrar katekolamin metabolit düzeyleri arasında anlamlı korelasyon saptanmıştır (p

🔖

Cite This Article

BOZKURT, O., ADIYAMAN, S. C., SAYDAM, B. Ö., SEÇİL, M., YENER, S., KOÇDOR, M. A., YÖRÜKOĞLU, K., DEMİR, Ö. (2022). Pheochromocytoma: 16 Years of Experience in a Single Center. Turkish Journal of Endocrinology and Metabolism, Cilt: 25 - Sayı: 1, 54–67. https://ajindex.com/articles/146565

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005
  2. [Crossref] [PubMed] 2. Farrugia FA, Charalampopoulos A. Pheochromocytoma. Endocr Regul. 2019
  3. [Crossref] [PubMed] 3. Gunawardane PTK, Grossman A. Phaeochromocytoma and paraganglioma. Adv Exp Med Biol. 2017
  4. [Crossref] [PubMed] 4. Costa MH, Ortiga-Carvalho TM, Violante AD, Vaisman M. Pheochromocytomas and paragangliomas: clinical and genetic approaches. Front Endocrinol (Lausanne). 2015
  5. [Crossref] [PubMed] [PMC] 5. Pamporaki C, Hamplova B, Peitzsch M, Prejbisz A, Beuschlein F, Timmers HJLM, Fassnacht M, Klink B, Lodish M, Stratakis CA, Huebner A, Fliedner S, Robledo M, Sinnott RO, Januszewicz A, Pacak K, Eisenhofer G. Characteristics of pediatric vs adult pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 2017
  6. [Crossref] [PubMed] [PMC] 6. Anderson GH Jr, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens. 1994
  7. [Crossref] [PubMed] 7. Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res. 2004
  8. [Crossref] [PubMed] 8. Sinclair AM, Isles CG, Brown I, Cameron H, Murray GD, Robertson JW. Secondary hypertension in a blood pressure clinic. Arch Intern Med. 1987
  9. [Crossref] [PubMed] 9. Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Alì A, Giovagnetti M, Opocher G, Angeli A. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000
  10. [Crossref] [PubMed] 10.Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF Jr
  11. Endocrine Society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014
  12. [Crossref] [PubMed] 11.Hamidi O, Young WF Jr, I-iguez-Ariza NM, Kittah NE, Gruber L, Bancos C, Tamhane S, Bancos I. Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years. J Clin Endocrinol Metab. 2017
  13. [Crossref] [PubMed] [PMC] 12.Bayraktar F, Kebapcilar L, Kocdor MA, Asa SL, Yesil S, Canda S, Demir T, Saklamaz A, Seçil M, Akinci B, Yener S, Comlekci A. Cushing's syndrome due to ectopic CRH secretion by adrenal p